BIOTECHNOLOGY
* Palo Alto-based Incyte Pharmaceuticals Inc. shares tumbled 18% amid concern the company will cancel plans to create a separate company to finance its effort to substantially expand its database of research on the human genetic makeup. Incyte shares fell $5 to close at $22.63 on Nasdaq. It was the biggest one-day percentage decline since the company’s initial public offering in November 1993.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
